Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb18087 · 1 trial · 2 indications
Treatment-related adverse events as assessed by CTCAE v4.03
Establishing a safe and tolerable dose of XmAb18087 administered by intravenous (IV) dosing in NET and GIST patients
| Arm | Type | Description |
|---|---|---|
| XmAb18087 | EXPERIMENTAL | XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles |
| Name | Type | Description |
|---|---|---|
| XmAb18087 | BIOLOGICAL | monoclonal bispecific antibody |
Inclusion Criteria: * Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization \[WHO\] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past ...
XmAb18087 is an investigational monoclonal antibody developed by Xencor, Inc. for the treatment of neuroendocrine tumors. It is a Phase 1 oncology candidate that has been studied in patients with neuroendocrine tumors and gastrointestinal neoplasms. XmAb18087 is not approved and remains in clinical development.
XmAb18087 is being developed for the treatment of neuroendocrine tumors, a type of cancer in the oncology therapeutic area. It was evaluated in a Phase 1 study that enrolled patients with neuroendocrine tumors and gastrointestinal neoplasms. The drug is investigational and has not been approved for any indication.
XmAb18087 targets SSTR2, also known as somatostatin receptor 2. It is a monoclonal antibody designed to bind this receptor, which is expressed on neuroendocrine tumors. Targeting SSTR2 is the mechanism underlying its development as an oncology therapeutic for neuroendocrine tumors.
XmAb18087 is being developed by Xencor, Inc., which trades on the Nasdaq under the ticker XNCR. Xencor is the sponsor of the clinical program evaluating the monoclonal antibody in neuroendocrine tumors and gastrointestinal neoplasms.
XmAb18087 is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication. The Phase 1 program studied the drug in patients with neuroendocrine tumors and gastrointestinal neoplasms.
XmAb18087 was studied in the Phase 1 trial NCT03411915, titled A Study of XmAb18087 in Subjects With NET and GIST. That trial enrolled 62 participants in the United States, included patients aged 12 years and older, and has been completed.